Last reviewed · How we verify
inflammation — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Hemorrhoid, Fissure, ProctalgiaSuppositories | BORNEOL | WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. | Non-Standardized Chemical Allergen [EPC] | |||
| Post - Vaccination | vaccination | Pfizer | Inactivated Poliovirus Vaccine [EPC] | Immune system |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in inflammation
- WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. · 1 drug in inflammation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in inflammation:
- inflammation treatment updates — RSS
- inflammation treatment updates — Atom
- inflammation treatment updates — JSON
Cite this brief
Drug Landscape (2026). inflammation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inflammation. Accessed 2026-06-10.
Related
- inflammation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing